Publikationen

  • Angela Besserer Corresponding Author, Sally Mutiara; Frank Breywisch; Markus Jungehülsing; Stefan Höcht: Long-term survival following trimodal therapy including hyperfractionated radiotherapy in parotid NUT carcinoma: A 29-month follow-up case report Open Access Subject Area: Oncology; Case Rep Oncol (2026); https://doi.org/10.1159/000551774
  • Jordan K. Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies. Ann Oncol. 2025 Jan;36(1):3-5 (IF 56,7)
  • Cherny NI, Nortjé N, Kelly R, Zimmermann C, Jordan K, Kreye G, Le NS, Adelson KB. A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?. ESMO Open. 2025 Jan 6;10(1):104099. doi: 10.1016/j.esmoop.2024.104099. [Epub ahead of print] Review. (IF: 7.1)
  • Jordan B, Jahn F, Jordan K. Peripheral neuropathy: from guidelines to clinical practise. Curr Opin Oncol. 2025 Jan 16 (IF 2,8)
  • Jahn F., Behlendorf T., Jordan, K. Behandlungsassoziierte Übelkeit und Erbrechen: Prophylaxe und Therapie. Im Fokus Onkologie 2025; 28(2) 62-67. Update der MASCC/ESMO-Leitlinie – was ist neu?
  • Park YH, Bianchini G, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol. 2025 Mar 19:1-12. doi: 10.1080/14796694.2025.2479417. Epub ahead of print. PMID: 40105595.
  • Jordan K, de Azambuja E, del Barrio MÁG, Jahn F, Di Palma M, Scotté F, et al. Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. European Journal of Cancer. 2025:115451.
  • Jordan, K, Jordan B, Vanden Burgt J, Jahn F. Exploring antiemetic strategies in hematologic malignancies: a comprehensive literature review and evaluation of antiemetic efficacy in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation. Support Care Cancer 33(7): 622. (IF: 3,2)
  • Neubauer A., Leithold C, Nitschmann S and Jordan K. New targeted treatment for tumor-associated cachexia : A breakthrough? Inn Med (Heidelb) 2025. (IF: 0,6)
  • Champiat S, Ouali K, Laparra A, Charalambous A, Di Palma M, Jordan K, Massard C, Aapro M, Scotte F. From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development. ESMO Open. 2025 Sep 17;10(10):105796. doi: 10.1016/j.esmoop.2025.105796. Epub ahead of print. PMID: 40967065. (IF: 7,1)
  • Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, Stimamiglio V, Alonzi A, Olivari Tilola S, Bonizzoni E, Brozos Vázquez E, Buchler T, Cheng Y, Christoph DC, García Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanová M, Aapro M. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. Ann Oncol. 2025 Oct 17:S0923-7534(25)04964-6. doi: 10.1016/j.annonc.2025.10.017. Epub ahead of print. PMID: 41110696 (IF: 65,4).
  • Dührsen U, Bockisch A, Hertenstein B, Karsten I, Kroschinsky F, Heuser M, Hochhaus A, Höffkes H, Behringer D, Prange-Krex G, Tometten M, Grieshammer M, Grigoleit G, Schmalz O, Jordan K, Bernhard H, Gaska T, Giagounidis A, Schroers R, Martens U, Held G, Klapper W, Jöckel K, Nonnemacher M, Hüttmann A, Wilop S, Tometten M, Korfel A, Keller U, de Wit M, Weissinger F, Stark U, Behringer D, Bückner U, Nückel H, Schroers R, Trenn G, Hertenstein B, Bernhard H, Heike M, Wörns M, Kroschinsky F, Prange-Krex G, Giagounidis A, Grigoleit G, Selbach J, Petrasch S, Balleisen J, Schütte J, Giagounidis A, Dienst A, Germing U, Dührsen U, von Verschuer U, Reimer P, Höffkes H, Runde V, Spohn C, Moeller R, Dürk H, Kofahl-Krause D, Heuser M, Witzens-Harig M, Müller-Tidow C, Martens U, Strumberg D, La Rosée P, Hochhaus A, Link H, Held G, Kneba M, Baldus C, Naumann R, Chemnitz J, Schulte K, Limmroth C, Schwarzer A, Niederwieser D, Platzbecker U, Heil G, Schwalenberg M, Grieshammer M, Beck C, Stephany M, Mesters R, Karsten I, Held H, Mahlmann S, Steiniger H, Gaska T, Südhoff T, Kreisel-Büstgens C, Moorahrend E, Maschmeyer G, Jordan K, Kloke O, Klein M, Höhler T, Grube M, Herr W, Hahn D, Raghavachar A, Schmalz O, Fett W, Sandmann M, Krohn T, Brenner W, Plotkin M, Franzius C, Kotzerke J, Hautzel H, Bockisch A, Hertel A, Bengel F, Haberkorn U, Freesmeyer M, Lützen U, Klein A, Kluge R, Larisch R, Fricke E, Holzinger J, Schäfer W, Weckesser M, Nyuyki F, Römer W, Brink I, Marienhagen J, Pöpperl G, Jöckel K, Nonnemacher M, Rekowski J, Scherag A, Neuhäuser M. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial. Blood Neoplasia. 2024; 1(3):100018.
  • Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F; participants of the MASCC/ESMO Consensus Conference 2022. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024 Feb;9(2):102195. (IF:7,3)
  • Habringer S, Demel UM, Fietz AK, Lammer F, Schroers R, Hofer S, Bairey O, Braess J, Meier-Stiegen AS, Stuhlmann R, Schmidt-Hieber M, Hoffmann J, Zinngrebe B, Kaiser U, Reimer P, Möhle R, Fix P, Höffkes HG, Langenkamp U, Büschenfelde CMZ, Hopfer O, Stoltefuß A, La Rosée P, Blasberg H, Jordan K, Kaun S, Meurer A, Unteroberdörster M, von Brünneck AC, Capper D, Heppner FL, Chapuy B, Janz M, Schwartz S, Konietschke F, Vajkoczy P, Korfel A, Keller U. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Eur J Cancer. 2024 Jan;196:113436. (IF: 8,4)
  • Link, H., Holtmann, L., Ortner, P., Diel, I, Ohlmann, C.-H., Jordan, K., Feyer, P., Detzner, M., Kerkmann, M. Leitlinienadhärenz bei Anämiemanagement, Neutropenieprophylaxe, Osteoprotektion, Immunglobulinsubstitution und Antiemese. Onkologie. 2024; 30(7): 592–600. https://doi.org/10.1007/s00761-024-01550-x
  • van Oorschot, B., Wiegering, A., Jordan, K., Höffken, K. Supportive Therapie – interdisziplinär und multiprofessionell. Onkologie. 2024, 30(7): 534–537. https://doi.org/10.1007/s00761-024-01536-9
  • Jahn, F., Behlendorf, T., & Jordan, K. Prophylaxe und Therapie Tumortherapie-induzierter Nausea und Emesis. Onkologie. 2024; 30(7): 556–564. https://doi.org/10.1007/s00761-024-01527-w
  • Jahn, F., Jordan, K. Übelkeit und Erbrechen. In: Jahn, P., Gaisser, A., Bana, M., Renner, C. (eds). Onkologische Krankenpflege. Springer, Berlin, Heidelberg; 2024. S. 415–433. (ISBN 978-3-662-67416-1) https://link.springer.com/chapter/10.1007/978-3-662-67417-8_20
  • Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, Cornelissen J. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285879. Epub ahead of print. PMID: 39113672.
  • Herrstedt J, Clark-Snow R, Ruhlmann CH, Jordan K, Scotté F. MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update. Support Care Cancer. 2023 Dec 22;32(1):57. (IF: 3,1)
  • Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.  Support Care Cancer. 2023 Dec 22;32(1):53 (IF: 3,1)
  • Scotté F, Schwartzberg L, Lihara H, Aapro M, Gralla R, Hesketh PJ, Jordan K, Chow R, Herrstedt J. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer. 2023 Dec 20;32(1):45. (IF: 3,1)
  • Ruhlmann CH, Jordan K, Jahn F, Maranzano E, Molassiotis A, Dennis K. 2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting. Support Care Cancer. 2023 Dec 15;32(1):26. (IF: 3,1)
  • Jahn, Franziska and Jordan, Karin. Leitlinien in der antiemetischen Prophylaxe und Therapie–Medikamentöse Tumortherapie. In: Schmoll HJ (Hrsg.). Kompendium Internistische Onkologie: Standards in Diagnostik und Therapie. Berlin, Heidelberg: Springer Berlin Heidelberg, 2023. 1-11.
  • Fleischer A, Zapf L, Allgaier J, Jordan K, Gelbrich G, Pryss R, Schobel J, Bittrich M, Einsele H, Kortüm M, Maatouk I, Weinhold N, Rasche L. A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol. 2023 Nov;149(14):12897-12902. (IF: 3,6)
  • Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K; ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023 May;34(5):452-467. (IF: 51,8)
  • John L, Miah K, Benner A, Mai EK, Kriegsmann K, Hundemer M, Kaudewitz D, Müller-Tidow C, Jordan K, Goldschmidt H, Raab MS, Giesen N. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma. Front Oncol. 2023;13:1078725. (IF: 6,2)
  • Neuendorff NR, Boshikova B, Frankenstein L, Kirchner M, Rohde C, Goldschmidt H, Frey N, Müller-Tidow C, Jordan K, Sauer S, Janssen M. Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma. Front Oncol. 2023 Apr 27;13:1168120. (IF: 6,2)
  • Hohloch K, Jordan K, Jahn, F. Antiemetische Therapie - Update 2023. InFo Hämatol Onkol. 2023; 26(4): 10–20.
  • Jordan K, De Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F. Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer. Oncol Res Treat. 2023;46(3):72-79. (IF: 2,4)
  • Zarkavelis G, Amylidi AL, Verbaanderd C, Cherny NI, Metaxas Y, de Vries EGE, Zygoura P, Amaral T, Jordan K, Strijbos M, Dafni U, Latino N, Galotti M, Lordick F, Giuliani R, Pignatti F, Pentheroudakis G. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2023 Feb;8(1):100604. (IF: 4,4)
  • Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F. Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer. Oncol Res Treat. 2023 Jan 13. Epub ahead of print. (IF: 2,8)
  • Zarkavelis G, Amylidi A, Verbaanderd C, Cherny N, Metaxas Y, de Vries E, Zygoura P, Amaral T, Jordan K, Strijbos M, Dafni U, Latino N, Galotti M, Lordick F, Giuliani R, Pignatti F, Pentheroudakis G. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2022/11; :100604.
  • Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec; 33(12):1217-1238.
  • Jahn F, Leithold C, Weiss St, Jordan K. 
  • Update der S3-Leitlinie „Supportive Therapie“ – Generierte Evidenz bewerten und umsetzen. Forum. 2022 Dez; 37(6): 442-448.
  • Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G.
    ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022 Nov; 33(11):1119-1133.
  • Tabatabai J, Schnitzler P, Prifert C, Schiller M, Weissbrich B, von Lilienfeld-Toal M, Teschner D, Jordan K, Müller-Tidow C, Egerer G, Giesen N.
    Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: analysis of clinical characteristics, nosocomial transmission and viral shedding. PLoS One. 2022; 17(7): e0271756. 
  • Jahn F, Wörmann B, Brandt J, Freidank A, Feyer P, Jordan K. 
    The Prevention and Treatment of Nausea and Vomiting During Tumor Therapy. Dtsch Arztebl Int. 2022 May 27; 119(21):382-392.
  • Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E. 
    Netupitant-Palonosetron (NEPA) in Preventing Chemotherapy-Induced Nausea and Vomiting: From Clinical Trials to Daily Practice. Curr Cancer Drug Targets. 2022; 22(10):806-824.
  • Taschenbuch Hämatologie und Onkologie www.onkologie2022.de mit Beiträgen von Prof. Dr. Karin Jordan
  • Feyer P, Jordan K.
    Radiotherapy induced nausea and vomiting: Prophylaxis and treatment. Updated 04/2022.
    https://www.uptodate.com/contents/radiotherapy-induced-nausea-and-vomiting-prophylaxis-and-treatment
  • Stämmler H, Sauer S, Kreutzer EP, Brandt J, Jordan K, Kreuter M, Kriegsmann M, Goldschmidt H, Müller-Tidow C, Egerer G, Kriegsmann K.
    Quality of Online Information on Multiple Myeloma Available for Laypersons. Curr Oncol. 2022; 29(7):4522-4540.
  • Dufner V, Kessler AF, Just L, Hau P, Bumes E, Pels H J, Grauer O M, Wiese B, Löhr M, Jordan K, Strik H.
    The Emesis Trial: Depressive Glioma Patients Are More Affected by Chemotherapy-Induced Nausea and Vomiting. Front Neurol. 2022; 13:773265.
  • Jordan K.
    Therapieinduzierte Diarrhoe. In: Honecker F, Claßen J, Preiß J, Dornoff W (Hrsg.). Taschenbuch Hämatologie und Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2022/23. 21. Auflage. Zuckerschwerdt Verlag; 2022. S. 271. (ISBN 978-3-86371-376-8)
  • Jordan K. 
    Nausea & Emesis – Prophylaxe und Therapie. In: Honecker F, Claßen J, Preiß J, Dornoff W(Hrsg.). Taschenbuch Hämatologie und Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2022/23. 21. Auflage. Zuckerschwerdt Verlag; 2022. S. 273. (ISBN 978-3-86371-376-8)
  • Yri OE, Jordan K, Kaasa S.
    Integration of Supportive and Palliative Care into Oncology. In: Bošnjak S M, Bozovic-Spasojevic I, Mountzios G and Wood J. ESMO Handbook of Supportive and Palliative Care. ESMO Handbook Series. ESMO Press; 2022. p1-10. (ISBN: 978-88-944465-4-8)
  • Maurus J, Terzer T, Benner A, Goisser S, Eidam A, Roth A, Jannsen M, Jaramillo S, Lorenz HM, Micol W, Hauer K, Müller-Tidow C, Bauer JM, Jordan K, Neuendorff NR.
    Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments. J Cachexia Sarcopenia Muscle. 2022 Feb; 13(1):264-275.
  • Goerling U, Gauler T, Dietz A, Grünwald V, Knipping S, Guntinas-Lichius O, Frickhofen N, Lindemann HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knödler M, Keilholz U, Klinghammer K
    Quality of life of patients with head and neck cancer receiving cetuximab, fluorouracil, cisplatin comparing to cetuximab, fluorouracil, cisplatin and docetaxel within the CEFCID trial. Journal of Cancer Research and Clinical Oncology 2022; 45: 319-324
  • Bergeron A, Mikulska M, De Greef J, Bondeelle L, Franquet T, Herrmann JL, Lange C, Spriet I, Akova M, Donnelly JP, Maertens J, Maschmeyer G, Rovira M, Goletti D, de la Camara R
    On behalf of the European Conference on Infections in Leukaemia group (2022): Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplantation: Guidelines from the 8th European Conference on Infections in Leukaemia (ECIL 8). The Lancet Infectious Diseases 27.05.2022 (epub ahead of print)
  • Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, Pagano L, Thiebaut-Bertrand A, Calandra T
    Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guideline by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia 2022; 36: 1215-1226
  • Albasanz-Puig A, Durà-Miralles X, Laporte-Amargós J, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo JM, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales HM, Brunel AS, García E, Isler B, Kern WV, Retamar P, Aguado JM, Montero M, Kanj S, Sipahi OR, Calik S, Márquez-Gómez I, Marín JI, Gomes M, Hemmati P, Araos R, Peghin M, Luis del Pozo J, Yáñez L, Tilley R, Manzur A, Novo A, Pallarès N, Bergas A, Carratala J, Gudiol C, Sastre E, Tubau F, Tebé C, Rodriguez-Arias M, Aguilar-Company J, Larrosa N, Cardozo C, García-Vidal C, Karim-Yaqub I, Greco R, Cichero P, Céspedes R, López-Soria L, Magnasco L, Fortún J, Torres D, Boté A, Espasa M, Hold Montaguti M, Manuel O, Bochud PY, Tabares-Carrasco S, Serrano-López J, Bertz H, Rieg S, Rodríguez-Baño J, de Cueto M, Lizasoain M, Horcajada JP, El Zein S, Jabbour JF, Uyan Önal A, Nazli-Zeka A, Palop B, Correa LC, Silva Tonha JP, Senos De Mello L, Maschmeyer G, Munita J, Castaldo N, Sangro P
    Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia. Microorganisms 2022; 10: 733
  • Ludwig WD, Ganser A, Maschmeyer G (2022):
    Onkologika. In: Ludwig WD, Mühlbauer B, Seifert R (Hrsg.): Arzneimittelverordnungsreport 2021, Springer Verlag GmbH, S. 579-638
  • Ludwig WD, Maschmeyer G, Ganser A (2022): Innovationen in der Onkologie – Wie stehen Nutzen und Kosten zueinander? InFo Hämatologie + Onkologie 25 (9): 3-5 (in Druck)
  • Maschmeyer G, Ludwig WD (2022): Frühe Nutzenbewertung bei Arzneimitteln in der Hämatologie und Onkologie. InFo Hämatologie + Onkologie 25 (9): 14-17 (in Druck)
  • Maschmeyer G, Loibl S, Fehm T, Hilgendorf I, Dittrich R (2022): Management onkologischer Erkrankungen in der Schwangerschaft. FORUM – Mitgliedermagazin der Deutschen Krebsgesellschaft (akzeptiert)
  • Jordan B, Benesova K, Hassel JC, Wick W, Jordan K.
    How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 2021 Dec; 6(6):100317.
  • Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N.
    Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev. 2021; 11:Cd012775.
  • Baertsch, M-A, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, Müller-Tidow C, Goldschmidt H, Raab M-S, Hillengass J, Giesen N.
    Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with our without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021 Sep 20; 13(18):4706.
  • Klein EM, Sauer S, Klein S, Tichy D, Benner A, Bertsch U, Brandt J, Kimmich C, Goldschmidt H, Müller-Tidow C, Jordan K, Giesen N.
    Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Cancers (Basel). 2021 Jul 9; 13(14):3439.
  • Jordan K, Leithold C.
    Fructoseunverträglichkeit berücksichtigen. Diskussionsbeitrag. Deutsches Ärzteblatt. 2021 Jun 4; 118(22):378.
  • Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K.
    Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. The Oncologist. 2021; 26(6):e1073-e1082.
  • Lacouture ME, Sibaud V, Gerber PA, Van den Hurk C, Fernández-Peñas P, Santini D, Jahn F, Jordan K.
    Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021; 32(2):157-170.
  • Roth P, Pace A, Le Rhun E, Weller M, Ay C, Cohen-Jonathan Moyal E, Commans M, Giusti R, Jordan K, Nishikawa R, Winkler F, Hong JT, Ruda R, Villà S, Taphoorn MJB, Wick W, Preusser M.
    Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(2):171-182. 
  • Jordan K, Jahn F, Feyer P, Karthaus M, Leithold C, Oechsle K, Strasser F, Wöll, E, Wörmann B.
    Onkopedia-Leitlinie: Antiemese bei medikamentöser Tumortherapie. Mai 2021.
  • Garassino MC, Giesen N, Grivas P, Jordan K, Lucibello F, Mir O, Pentheroudakis G, Scotté F, Von Lilienfeld-Toal M, Curigliano G, Haanen J, Liebert UG, Lordick F, Melero I, Pietsch C, Peters S.
    COVID-19 vaccination in cancer patients: ESMO statements. Updated 12/2021. 
  • Dajani, O. und Jordan, K.
    Disease-modifying therapies in advanced cancer: medical treatment. In: Cherny N, Fallon M, Kaasa S, Portenoy R und Currow D (Editors). Oxford Textbook of Palliative Medicine. 6th Edition. Oxford University Press; 2021. p800–C14.2.P63. (ISBN: 9780198821328)
  • Damaschin C, Goergen H, Kreissl S, Plütschow A, Breywisch F, Mathas S, Meissner J, Sökler M, Topp MS, Vucinic V, Zimmermann A, von Tresckow B, Fuchs M, Engert A, Borchmann P, Eichenauer DA Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia 2022 Feb; 36(2):580-582. doi: 10.1038/s41375-021-01386-z. Epub 2021 Aug 18.PMID: 34408266
  • Jaekel N, Krahl R, Haenel M, Maschmeyer G, Herbst R, Schulze S, Wang SY, Kahl C, Jaspers S, Wass M, Sayer HG, Koeppe-Bauernfeind N, Brosteanu O, Niederwieser D, Al-Ali HK: 
    Response-adapted sequential azacitidine and chemotherapy in patients > 60 years with newly diagnosed acute myeloid leukemia: a multicenter study of the East German Study Group (OSHO). Haematologica 2021 (eingereicht)
  • Claßen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Durán Graeff L, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ
    Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematolopgy 2021; 100: 1603-1620
  • Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M, Penack O, Ruhnke M, Weissinger F, Cornely OA, Maschmeyer G
    Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology 2021; 100: 321-336
  • Hemmati P, Fischer D, Breywisch F, Wohlfarth S, Kramer M, Paland M, Badakhshi H, Ripberger G, Maschmeyer G
    Maintaining an adult hematology/oncology service at a tertiary care center during the SARS-CoV-2 pandemic: an eight-week-experience with a newly implemented procedural plan. Journal of Cancer Research and Clinical Oncology 2021; 44: 354-359
  • Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Niederwieser D, Al-Ali HK
    Incidence, therapy and outcome of relapsed acute myeloid leukemia: results from two East German Study Group Hematology and Oncology (OSHO) trials with real world AML- age distribution. Annals of Hematology 2021; 100: 2387-2398
  • Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Neumann T, Schneidewind L, Niederwieser D, Dölken G, Schmidt CA 
    Allogeneic stem cell transplantation for mantle cell lymphoma - update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). Annals of Hematology 2021; 100: 1569-1577
  • Bachmann F, Schreder M, Engelhardt M, Langer C, Wolleschak D, Mügge LO, Dürk H, Schäfer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Grube M, V Metzler I, Bassermann F, Metzner B, Röllig C, Hertenstein B, Khandanpour C, Dechow T, Hebart H, Jung W, Theurich S, Maschmeyer G, Salwender H, Hess G, Bittrich M, Rasche L, Brioli A, Eckardt KU, Straka C, Held S, Einsele H, Knop S
    Kinetics of renal function during induction in newly diagnosed multiple myeloma: Results of two prospective studies by the German Myeloma Study Group DSMM. Cancers (Basel) 2021; 13: 1322
  • Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P
    On behalf of the German Hodgkin Study Group (2021): PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. The Lancet Haematology 2021; 8: e398–409
  • Cordonnier C, Ljungman P, Cesaro S, Hirsch HH, Maschmeyer G, von Lilienfeld-Toal M, Vehreschild M, Mikulska M, Emonts M, Gennery AR, Neofytos D, Bochud PY, Einsele H, Johan Maertens J
    The EHA Research Roadmap: Infections in Hematology. HemaSphere 2021; 5: e662
  • Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales H, Brunel AS, García E, Isler B, Kern WV, Morales I, Maestro-de la Calle G, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmati P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J;
    IRONIC Study Group. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2020; 64:e02494-19.
  • Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P.
    Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Journal of Cancer Research and Clinical Oncology 2020; 146:1065-77.
  • Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, Maschmeyer G, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S.
    Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses 2020; 63:653-82.
  • Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt DT, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler J, Pelzer U, Bischoff S, Bahra M, Oettle H
    CONKO-006: a randomized double-blind phase IIb study of additive therapy with gemcitabine + sorafenib/placebo for patients with R1-resection of pancreatic cancer – final results. European Journal of Cancer 2020; 138: 172-181
  • Pouyiourou M, Meyer A, Stroux A Viardot A, La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz C
    First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A – results of a retrospective analysis. Annals of Hematology 2020; 99: 2821-2829
  • Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A
    Mucormycosis ECMM MSG Global Guideline Writing Group: Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet Infectious Diseases 2020; 19: e405-e421
  • Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz- Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales H, Brunel AS, García E, Isler B, Kern WV, Morales I, Maestro-de la Calle G, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmati P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J;
    IRONIC Study Group: Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2020; 64: e02494-19
  • Maschmeyer G (2020): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC Anderson).
    In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 983-994
  • Maschmeyer G (2020): Onkologische Notfälle (R Gucalp, JP Dutcher). In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 635-647
  • Maschmeyer G (2020): Spätfolgen von Krebserkrankungen und ihrer Behandlung (CE Freter, DL Longo). In: Suttorp N et al (Hrsg.): Harrisons Innere Medizin, Thieme-Verlag/ABW Wissenschaftsverlag Berlin, S. 837-842
Startseite
Bereich Hämatologie
Bereich Onkologie
Bereich Palliativmedizin
Bereich Ambulanz und Tagesklinik
Bereich Hämostaseologie
Leistungsspektrum
Tumorboards/Tumorkonferenzen
Begleitende Angebote
Unser Team
Klinische Studien
Internationale Vernetzung
S3 Leitlinie Supportive Therapie
Publikationen
Historie der Klinik
Ihre Karriere bei uns
COVID-19-Informationen